UCB announces new three-year data from Phase 3 trials on BIMZELX

UCB (UCBJF), a global biopharmaceutical company, announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX in adults with active psoriatic arthritis, PsA, non-radiographic axial spondyloarthritis with objective signs of inflammation, and ankylosing spondylitis, AS. Key Findings: Sustained improvements across stringent measures of disease in patients with psoriatic arthritis: One-year improvements were sustained to three years across measures of peripheral arthritis, dactylitis, enthesitis, skin psoriasis, and nail psoriasis – indicating sustained inflammation control. Sustained clinical response to stringent endpoints in half of patients with axial spondyloarthritis. First real-world findings demonstrate rapid quality of life improvements in patients with PsA, nr-axSpA, and AS.